Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.8171
Abstract: Importance The drug HD201 is a biosimilar candidate for breast cancer treatment as the reference trastuzumab. Objective To compare the efficacy of HD201 with referent trastuzumab. Design, Setting, and Participants This randomized clinical trial (TROIKA)… read more here.
Keywords: breast cancer; trastuzumab; hd201 referent; referent trastuzumab ... See more keywords